Press Release: February’s themed issue of the Journal of Managed Care & Specialty Pharmacy (JMCP) examines challenges that managed care pharmacists face in administering oncology therapies, including considerations around patient-reported outcomes and the role of caregivers.
On February 1, 2017, CMS released its 2018 Draft Call Letter. Overall, the Draft Call Letter does not contain any major changes that are of serious concern to managed care pharmacy. However,
there are several provisions worth noting, such as changes to Star Ratings and efforts to reduce opioid overutilization.
In January 2017, AMCP co-sponsored a conference with the PhRMA Foundation on the use of CER and PCOR by patients, clinicians, and payers. The conference centered on existing strategies to enhance uptake and use of CER/PCOR, as well as the needs and gaps in the uptake and use of CER/PCOR evidence.
Press Release: The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) is pleased to announce the addition of a new participating organization, Apobiologix.
Press Release: The Academy of Managed Care Pharmacy (AMCP) commends the Food and Drug Administration (FDA) for its release today of draft guidance clarifying how biopharmaceutical companies and population health decision makers can proactively share clinical and economic information on both FDA approved products as well as emerging therapies awaiting FDA approval.
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 30 health care organizations committed to aligning the Substance Abuse and Mental Health Service Administration's (SAMHSA) final rule on Confidentiality of Alcohol and Drug Abuse Patient Records, 42 Code of Federal Regulations Part 2 (Part 2) with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to allow appropriate access to patient information that is essential for providing whole-person care, issued the following statement in response to the Part 2 final rule.